January 26, 2016 / 6:27 AM / 2 years ago

Actelion receives Canada approval for Uptravi

A general view shows Swiss biotech group Actelion Headquarters in Allschwil near Basel February 17, 2015. REUTERS/Arnd Wiegmann

ZURICH (Reuters) - Actelion Ltd ATLN.VX, Europe’s biggest biotech firm, said on Tuesday that Health Canada had granted a notice of compliance for Uptravi, a new pulmonary arterial hypertension medicine.

The approval is “a major milestone”, Chief Executive Jean-Paul Clozel said in a statement, adding that the company is working to make the drug available to patients in Canada “as soon as possible”.

Analysts have said Uptravi could reap more than $1 billion in global sales annually at its peak.

Reporting by Joshua Franklin; editing by Brenna Hughes Neghaiwi

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below